Beta‐2‐glycoprotein I antibodies in patients with thrombosis

REFERENCES

• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are direc-ted against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4.
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544–7.
   Google Scholar
• Puurunen M, Vaarala 0, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80: 16–22.
   Google Scholar
• Sanmarco M, Soler C, Christides C, Raoult D, Weiller PJ, Gerolami V, Bernard D. Prevalence and clinical significance of IgG isotype anti-I32-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardio-lipin antibodies. J Lab Clin Med 1997; 129: 499–506.
   Google Scholar
• Arnout J, Vermylen J. Mechanism of action of beta-2-glycoprotein I-dependent lupus anticoagu-lants. Lupus 1998; 7 Suppl 2: S23–8.
   PubMed Web of Science ®Google Scholar
• Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantibodies to 132-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25: 667–74.
   PubMed Web of Science ®Google Scholar
• Voss A, Jacobsen S, Heegaard NH. Association of beta-2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus 2001; 10: 533–8.
   Google Scholar
• Levine JS, Branch DW, Rauch J. The antiphos-pholipid syndrome. N Engl J Med 2002; 346: 752— 63.
   PubMed Web of Science ®Google Scholar
• Jouhikainen T, Julkunen H, Vaarala 0, Leirisalo-Repo M, Stephansson E, Vahtera E, Palosuo T, Myllylä G. Antiphospholipid antibodies and thrombosis in systemic lupus erythematosus: com-parison of three lupus anticoagulant assays and anticardiolipin ELISA in 188 patients. Blood Coag Fibrinol 1992; 3: 407–14.
   Google Scholar
• Erickson EN Jr, Najmey SS, Keil LB, El-Kadi HS, DeBari VA. Reference calibrators for IgG anti-bodies to beta-2-glycoprotein I: preparation, pro-perties and availability to investigators. Clin Chem 1996; 42: 1116–7.
   Google Scholar
• Lewis S, Keil LB, Binder WL, DeBari VA. Standardized measurement of major immuno-globulin class (IgG, IgA, and IgM) antibodies to beta-2-glycoprotein I in patients with antiphos-pholipid syndrome. J Clin Lab Anal 1998; 12: 293–7.
   PubMed Web of Science ®Google Scholar
• Vaarala 0, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41: 8–15.
   PubMedGoogle Scholar
• McNally T, Purdy G, Mackie U, Machin SJ, Isenberg DA. The use of an anti-132-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 471–3.
   Google Scholar
• Vila P, McHernández MC, Lopez-Fernandez MF, Baffle J. Prevalence, follow-up and clinical signi-ficance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209–13.
   PubMed Web of Science ®Google Scholar
• Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704–15.
   PubMed Web of Science ®Google Scholar
• Guglielmone H, Vitozzi S, Elbarcha 0, Fernandez E. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis 2001; 60: 500–4.
   Google Scholar
• Myers B, Dolan G, Gould J. Audit of laboratory investigation of antiphospholipid syndrome. Br J Haematol 2001; 115: 229.
   Google Scholar
• H6rkk6 S, Olee T, Mo L, ym. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001; 103: 941–6.
   Google Scholar
• Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syn-dromes: a primary variant with antibodies to beta-2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101: 472–81.
   Google Scholar
• Silver RM, Porter TF, van Leeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: clinical consequences of "low titers". Obstet Gynecol 1996; 87: 494–500.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Brancaccio V, Moia MYM. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 318–9.
   Google Scholar
• Abuaf N, Meyer 0, Laperche S, ym. Report of the first French anticardiolipin antibodies standardi-zation workshop. Clin Rev Allergy Immunol 1995; 13: 25–38.
   Google Scholar
• Ginsberg JS, Wells PS, Brill-Edwards P, ym. Antiphospholipid antibodies and venous thrombo-embolism. Blood 1995; 86: 3685–91.
   Google Scholar
• D'Angelo A, Safa 0, Crippa L, Garlando A, Sabbadini MG, D'Angelo S. Relationship of lupus anticoagulant, anticardiolipin, anti-beta2-GPI and anti-prothrombin antibodies with history of throm-bosis in patients with the clinical suspicion of APA-syndrome. Thromb Haemost 1997; 78: 967–8.
   Google Scholar
• Galli M. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome? Haemostasis 2000; 30 Suppl 2: 57–62.
   PubMedGoogle Scholar
• Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inac-curacies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997; 77: 934–7.
   Google Scholar
• Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy. Blood Coag Fibrinol 1990; 1: 627–32.
   PubMedGoogle Scholar
• Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to beta-2-glycoprotein I—a specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997; 109: 304–9.
   PubMed Web of Science ®Google Scholar
• Brey RL, Abbott RD, Club JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischaemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001; 32: 1701–6.
   Google Scholar
• Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syn-drome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001; 10: 457–60.
   Google Scholar
• Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, Boffa M-C, Arvieux J. Inter-laboratory variability of anti-I32-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66–73.
   Google Scholar
• Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999; 25: 333–50.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. Q J Med 2000; 93: 523–30.
   Google Scholar